References
- Powles T, Carrol D, Chowdhury S, et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med. 2021;27(5):793–801.
- Börcsök J, Diossy M, Sztupinszki S, et al. Detection of molecular signatures of homologous recombination deficiency in bladder cancer. Clin Cancer Res. 2021. doi: https://doi.org/10.1158/1078-0432.CCR-20-5037
- Sargent D, Conley B, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23(9):2020–2027.
- Hoadley K, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291–304.
- Bellmunt J, Hussain M, Gschwend J, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525–537.